Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 7/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.40 |
| ▸ | USP14 | P54578 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 3/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29973124 | 0.84 | CHRM4 (0.54) | CHRM4CHRM2ACACB | |
| SCHEMBL28377314 | 0.83 | CHRM4 (0.58) | CHRM4CHRM2CHRM1HTR3AUSP30 | |
| SCHEMBL31614778 | 0.82 | MGLL (0.44) | CHRM4CHRM2MAPT | |
| SCHEMBL30455908 | 0.81 | CHRM4 (0.57) | CHRM4CHRM2CHRM1ACACB | |
| SCHEMBL21847675 | 0.80 | CHRM4 (0.57) | CHRM4CHRM2ACACB | |
| SCHEMBL21847696 | 0.80 | CHRM4 (0.57) | CHRM4CHRM2MAPTACACB | |
| SCHEMBL31647857 | 0.79 | CHRM4 (0.49) | CHRM4KDM4EPOLBMAPT | |
| SCHEMBL21847855 | 0.78 | CHRM4 (0.60) | CHRM4CHRM2ACACB | |
| Fluoride Ion SCHEMBL31647774 | 0.78 | CHRM4 (0.55) | CHRM4CHRM2MAPTACACB | |
| SCHEMBL29839965 | 0.78 | CHRM4 (0.60) | CHRM4CHRM2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905284-B2 | 5,7-dihydro-pyrrolo-pyridine derivatives | PFIZER INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230192690-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | PFIZER (US) | 2023-06-22 | — | — | US | disclosed |
| EP-3642202-B1 | DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | PFIZER (US) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192690-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | CHRM1, CHRM5, CHRM2 | CHRM4 4/4885CHRM2 3/4885USP14 4717/4885 |
| US-11905284-B2 | 5,7-dihydro-pyrrolo-pyridine derivatives | CHRM1, CHRM5, CHRM2 | CHRM4 4/4885CHRM2 3/4885USP14 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.